Literature DB >> 9000387

Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization.

M De Santis1, S Alborino, P L Tartoni, P Torricelli, A Casolo, R Romagnoli.   

Abstract

Opinion is divided regarding the influence of iodized oil on MRI signal intensity of hepatic tumours treated with transcatheter arterial chemoembolization (TACE), in which lipiodol deposits. The aim of our study was to ascertain whether or not lipiodol directly influences the MRI signal intensity of hepatocellular carcinoma (HCC) treated by TACE and that of the surrounding liver. Thirteen patients with HCC were studied retrospectively. CT and MRI scans were performed both before and 3 months after TACE. The CT scan was performed to check whether embolized nodules contained lipiodol and how lipiodol was distributed within them. In addition, eight patients were examined prospectively within 7 days after TACE. In these patients a CT scan was performed to see how lipiodol was distributed in the neoplastic nodules and in normal hepatic parenchyma. In the first group of patients the contrast-to-noise (C/N) ratio on T1-weighted (T1W) images and the T2 relaxation time on T2-weighted (T2W) images were calculated for both neoplasm and surrounding liver. In the second group of patients we also measured the signal intensity of non-neoplastic liver that was either permeated or not permeated by lipiodol. The data were analysed with Wilcoxon's test. On T1W images we observed that the retention of lipiodol increased the C/N ratio in all the tumours studied within 1 week after TACE. In the patients studied 3 months after TACE the C/N ratio was not significantly increased. On T2W images lipiodol retention did not change tumour signal intensity. The iodized oil did not change the signal intensity of the liver surrounding the tumour, in comparison with the liver not permeated by lipiodol, on either T1W or T2W images. The results indicate that lipiodol does not modify the signal intensity in non-neoplastic hepatic parenchyma in which it is deposited; after 3 months it does not significantly affect the signal of the tumours that accumulated it. Lipiodol produces a high signal on T1W images over the first few days following TACE in those tumours in which it is deposited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000387     DOI: 10.1007/s003300050099

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

1.  Chemical shift MR imaging methods for the quantification of transcatheter lipiodol delivery to the liver: preclinical feasibility studies in a rodent model.

Authors:  Xiaoming Yin; Yang Guo; Weiguo Li; Eugene Huo; Zhuoli Zhang; Jodi Nicolai; Robert A Kleps; Diego Hernando; Aggelos K Katsaggelos; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2012-06       Impact factor: 11.105

2.  An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging features.

Authors:  Xin Li; Chuan-Sheng Zheng; Gan-Sheng Feng; Chen-Kai Zhuo; Jun-Gong Zhao; Xi Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 3.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

4.  Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor.

Authors:  Manon Buijs; Josephina A Vossen; Jean-Francois H Geschwind; Nouha Salibi; Li Pan; Veronica Prieto Ventura; Eleni Liapi; Kwang Hun Lee; Ihab R Kamel
Journal:  J Vasc Interv Radiol       Date:  2011-05-28       Impact factor: 3.464

5.  Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma.

Authors:  M Bhat; M Hassanain; E Simoneau; G N Tzimas; P Chaudhury; M Deschenes; D Valenti; P Ghali; P Wong; T Cabrera; J Barkun; J I Tchervenkov; P Metrakos
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

6.  Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE.

Authors:  Fu-Hua Yan; Kang-Rong Zhou; Jie-Min Cheng; Jian-Hua Wang; Zhi-Ping Yan; Reng-Rong Da; Jia Fan; Yuan Ji
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

7.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura Kulik; Robert K Ryu; Mary F Mulcahy; Talia Baker; Vanessa Gates; Ritu Nayar; Ed Wang; Frank H Miller; Kent T Sato; Reed A Omary; Michael Abecassis; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-05       Impact factor: 2.740

8.  Hepatocellular carcinoma after transcatheter arterial chemoembolization: difficulties on imaging follow-up.

Authors:  Jeong Sik Yu
Journal:  Korean J Radiol       Date:  2005 Jul-Sep       Impact factor: 3.500

9.  Image-Based Analysis of Tumor Localization After Intra-Arterial Delivery of Technetium-99m-Labeled SPIO Using SPECT/CT and MRI.

Authors:  In Joon Lee; Ji Yong Park; Young-Il Kim; Yun-Sang Lee; Jae Min Jeong; Jaeil Kim; Euishin Edmund Kim; Keon Wook Kang; Dong Soo Lee; Seonji Jeong; Eun Jeong Kim; Young Il Kim; Jin Wook Chung
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

10.  Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance.

Authors:  Daryl Lim Joon; Alexandra Berlangieri; Benjamin Harris; Mark Tacey; Rachel O'Meara; Brent Pitt; Angela Viotto; Kerryn Brown; Michal Schneider; Nathan Lawrentschuk; Shomik Sengupta; Colleen Berry; Trish Jenkins; Michael Chao; Morikatsu Wada; Farshad Foroudi; Vincent Khoo
Journal:  Phys Imaging Radiat Oncol       Date:  2021-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.